Atopic Dermatitis

>

Latest News

Dupilumab is Safe and Effective Across Pediatric Populations with Severe Atopic Dermatitis: New Meta-Analysis
Dupilumab is Safe and Effective Across Pediatric Populations with Severe Atopic Dermatitis: New Meta-Analysis

March 31st 2025

Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.

April Issue of Patient Care Digital Edition is Now Live
April Issue of Patient Care Digital Edition is Now Live

March 27th 2025

Delgocitinib Cream Shows "Super Response" in Chronic Hand Eczema: Daily Dose / image credit: ©New Africa/AdobeStock
Delgocitinib Cream Shows "Super Response" in Chronic Hand Eczema: Daily Dose

March 26th 2025

OX40 Inhibitor Rocatinlimab Found Effective for Atopic Dermatitis: Daily Dose / image credit: ©New Africa/AdobeStock
OX40 Inhibitor Rocatinlimab Found Effective for Atopic Dermatitis: Daily Dose

March 25th 2025

Millions of US Adults Have Multiple Forms of Eczema, Study Finds
Millions of US Adults Have Multiple Forms of Eczema, Study Finds

March 21st 2025

More News

© 2025 MJH Life Sciences

All rights reserved.